<DOC>
	<DOCNO>NCT03059641</DOCNO>
	<brief_summary>To evaluate concordance sensitize mutation detect paired plasma tissue sample ; correlation clonal status sensitize mutation target therapy response ; prognostic impact relative abundance sensitize / resistance mutation .</brief_summary>
	<brief_title>Therapeutic ResistAnce Clonal Evolution Assessed With Liquid Biopsy NSCLC Patients China</brief_title>
	<detailed_description>In study , 500 advance NSCLC patient recruit . All patient receive biopsy genotype assay circultating tumor DNA ( ctDNA ) liquid biopsy . Patients carry actionable EGFR mutation , ROS1 fusion , ALK fusion MET exon 14 skip mutation receive TKI treatment accord guideline . During TKI treatment , every patient take liquid biopsy assay monitor mutation status . The study end patient progressive disease ( PD ) target lesion .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Provision inform consent Newly diagnose histological cytological confirm stage IIIBIV lung adenocarcinoma nonsmoking squamous cell carcinoma patient accord AJCC staging system . The stage IV lung cancer brain metastasis diagnose image enhance CT respectively ECOG performance status 02 expect 6 month survival time Willingness comply require protocol give permission use data clinical research product development Patients primary cancer Patients symptomatic brain metastasis , complication associate brain metastasis cognitive disorder Patients fail either plasma tissue sample QC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Next Generation Sequencing ( NGS )</keyword>
	<keyword>Tyrosine Kinase Inhibitor ( TKI )</keyword>
	<keyword>liquid biopsy</keyword>
	<keyword>EGFR Gene mutation</keyword>
</DOC>